Pharmaceutical company manufacturing and selling various types of medicine in mainland China; founded 1995, the largest psychotropic drug producer in China. Listed on the Hong Kong Stock Exchange (3692) since June 2019.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2018
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Hansoh Pharma announced that its self-developed Class 1 injectable new drug HS-20197 has received a Clinical Trial Approval Notice from China's National Medical Products Administration. - The approval covers clinical trials of HS-20197 in patients with advanced solid tumors, according to a report from the Economic Information Agency. - HS-20197 is an internally developed injectable candidate, and the NMPA clearance allows Hansoh Pharma to begin clinical evaluation in this tumor setting.
- The Phase III ARTEMIS-008 trial showed risvutatug rezetecan reduced the risk of death by 54% versus topotecan in relapsed small-cell lung cancer. - Median overall survival reached 18.5 months with Ris-Rez versus 10.3 months with topotecan after a median follow-up of 12.2 months. - Grade 3 or higher treatment-related adverse events occurred in 60.9% of Ris-Rez patients versus 78.2% with topotecan, mostly hematologic toxicities. - GSK, which holds ex-China rights to the B7-H3-directed antibody-drug conjugate, is advancing a global development program including the Phase III EMBOLD SCLC-301 trial.
